Pacira's Exparel Positive in Phase IV Studies - Analyst Blog

By
A A A

Pacira Pharmaceuticals, Inc. ( PCRX ) announced the results of a series of open-label prospective phase IV studies (IMPROVE) on its pain management drug, Exparel (bupivacaine liposome injectable suspension) in post-surgical patients. The studies (n=191) made a pooled analysis of the data to evaluate the post-surgical narcotic use and pharmacoeconomic benefit of Exparel in comparison to an opioid-based pain management regimen.

Pacira conducted the studies in patients who had undergone three common gastrointestinal surgeries−open colectomy, laparoscopic colectomy and ileostomy reversal.

Results showed that treatment with the Exparel-based multimodal analgesic regimen led to 60% and 67% reduction in total narcotic consumption and incidence of opioid-related adverse events, respectively. The median length of hospital stay was reduced by 1.4 day and resulted in $2,455 savings in mean per-patient hospitalization costs.

We note that Exparel is already approved for administration into the surgical site to produce post-surgical analgesia for up to 72 hours. It was launched in the U.S. in Apr 2012. In 2013, Exparel generated net sales of $76.2 million.

We remind investors that in Mar 2014, the FDA approved an additional bulk manufacturing suite (Suite C) for Exparel at the current manufacturing site in San Diego. Expansion of manufacturing capacity has allowed Pacira to meet the growing market demand for multimodal pain management regimen.

We are pleased to see Pacira's label expansion efforts for Exparel. Pacira is currently evaluating Exparel for several indications, including nerve block administration. The company filed a supplemental New Drug Application (sNDA) for Exparel for femoral nerve block in total knee arthroplasty patients last month.

We expect investor focus to remain on updates regarding Exparel for femoral nerve block.

Pacira carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. ( ANIP ), ARIAD Pharmaceuticals Inc. ( ARIA ) and Endo International plc ( ENDP ). While ANI Pharma carries a Zacks Rank #1 (Strong Buy), ARIAD and Endo International hold a Zacks Rank #2 (Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ENDO INTL PLC (ENDP): Free Stock Analysis Report

ARIAD PHARMA (ARIA): Free Stock Analysis Report

PACIRA PHARMACT (PCRX): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ENDP , ARIA , PCRX , ANIP

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

24,816,666
  • $103.50 ▲ 0.98%
23,585,783
  • $10.48 ▲ 12.09%
21,945,368
  • $16.1501 ▲ 0.37%
17,718,909
  • $19.91 ▲ 1.74%
15,846,661
  • $12.54 ▲ 7.36%
14,825,613
  • $50.97 ▲ 2.45%
14,387,253
    $3.63 unch
13,803,438
  • $75.6218 ▲ 1.07%
As of 9/2/2014, 11:41 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com